Clinical Research Directory
Browse clinical research sites, groups, and studies.
The EMPA-FIT Study
Sponsor: Seoul National University Bundang Hospital
Summary
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
Official title: Empagliflozin Versus Metformin for Glucose Variability and Metabolic Outcomes in Drug-Naïve Type 2 Diabetes
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2024-01-01
Completion Date
2025-12-31
Last Updated
2025-02-26
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 mg
The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
Metformin
The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
Locations (1)
SNUBH
Seongnam, South Korea